Inogen Announces First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stifel Raises Price Target After Inogen (INGN) Reports Better-Than-Expected 1Q
May 10, 2016 9:48 AM EDTStifel reiterated a Buy rating on Inogen, Inc (NASDAQ: INGN), and raised the price target to $52.00 (from $46.00), following the company's 1Q earnings report. INGN reported revenue of $43m, ahead of the consensus estimate of ~$41.7m. The strongest contributor to growth was the domestic business-to-business channel.... More
Inogen, Inc (INGN) Product Cycle Is More Important Than EBITDA Miss - Needham & Company
May 10, 2016 6:25 AM EDTNeedham & Company analyst, Mike Matson, thinks there is a buying opportunity after Inogen, Inc (NASDAQ: INGN) beat consensus revenue but missed consensus EBITDA in 1Q16. Management maintained 2016 guidance but the analyst upped his PT to $58 based on 5x 2017 sales.
Domestic business-to-business... More
Inogen (INGN) Reports Q1 EPS of 11c, Maintains Guidance
May 9, 2016 5:19 PM EDTInogen (NASDAQ: INGN) reported Q1 EPS of $0.11, may not compare to the analyst estimate of $0.12. Revenue for the quarter came in at $43 million versus the consensus estimate of $41.75 million.
Financial Outlook for 2016
The Company confirmed its 2016 revenue guidance of $187 to $191 million, which represents year-over-year growth of 17.6% to 20.1%. The Company continues to expect total revenue headwind from Medicare competitive bidding reimbursement reductions to be 3.5... More
